CLINICAL_TRIALS
trial_result
· 2012-08-23
Clinical Trial Update: Open Study of CEP-701 in Patients With Refractory Acute Myeloid Leukemia With FLT-3 Mutation [Phase 2]
Summary
Phase 2 trial of CEP-701 (lestaurtinib) in patients with refractory acute myeloid leukemia with FLT-3 mutation has completed.
Upgrade for the full analysis, importance score, and drug timeline.
Diseases / indications
Drugs mentioned
Snippet
Sponsor: Cephalon | Conditions: Leukemia, Myeloid | Phase 2 | Status: COMPLETED